United Therapeutics Stock Investor Sentiment
| UTHR Stock | USD 372.89 5.53 1.51% |
Slightly above 67 percent of all United Therapeutics' retail investors are curious in acquiring. The analysis of the overall investor sentiment regarding United Therapeutics suggests that quite a few traders are confidant. United Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in United Therapeutics. Many technical investors use United Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Panic Vs Confidence
67
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use United Therapeutics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward United Therapeutics.
News SentimentBullish | Hype SentimentBullish | Insider SentimentDisposing |
United Historical Sentiment
Although United Therapeutics' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding United, such as negative comments on social media and news outlets, may cause fear in the market and push United Therapeutics' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of United.
United |
United Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards United Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
United Therapeutics Historical Investor Sentiment
Investor biases related to United Therapeutics' public news can be used to forecast risks associated with an investment in United. The trend in average sentiment can be used to explain how an investor holding United can time the market purely based on public headlines and social activities around United Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
United Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for United Therapeutics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average United Therapeutics news discussions. The higher the estimate score, the more favorable the investor's outlook on United Therapeutics.
Far too much social signal, news, headlines, and media speculation about United Therapeutics that are available to investors today. That information is available publicly through United media outlets and privately through word of mouth or via United internal channels. However, regardless of the origin, that massive amount of United data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of United Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of United Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to United Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive United Therapeutics alpha.
United Therapeutics Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Acquisition by Rothblatt Martine A of 3600 shares of United Therapeutics at 129.49 subject to Rule 16b-3 | 08/30/2024 |
2 | Disposition of 3400 shares by James Edgemond of United Therapeutics at 362.37 subject to Rule 16b-3 | 09/03/2024 |
3 | Disposition of 4300 shares by Patusky Christopher of United Therapeutics at 353.3567 subject to Rule 16b-3 | 09/04/2024 |
4 | Acquisition by Patusky Christopher of 700 shares of United Therapeutics at 175.43 subject to Rule 16b-3 | 09/13/2024 |
5 | Disposition of 3400 shares by James Edgemond of United Therapeutics at 355.88 subject to Rule 16b-3 | 10/14/2024 |
6 | 100 Invested In United Therapeutics 5 Years Ago Would Be Worth This Much Today | 10/15/2024 |
7 | Earnings Preview Ardelyx Q3 Earnings Expected to Decline | 10/24/2024 |
8 | Earnings call United Therapeutics reports robust Q3 growth, eyes future milestones | 10/31/2024 |
9 | United Therapeutics is a Top-Ranked Growth Stock Should You Buy | 11/05/2024 |
10 | Disposition of 300 shares by Michael Benkowitz of United Therapeutics at 8.9 subject to Rule 16b-3 | 11/06/2024 |
11 | Disposition of 1855 shares by Michael Benkowitz of United Therapeutics at 401.6542 subject to Rule 16b-3 | 11/07/2024 |
12 | MannKind Q3 2024 Earnings Call Transcript | 11/08/2024 |
13 | Insider Sale Director Judy Olian Sells Shares of United Therapeutics Corp | 11/13/2024 |
14 | Entropy Technologies LP Decreases Stake in United Therapeutics Co. | 11/15/2024 |
15 | Disposition of 237 shares by Michael Benkowitz of United Therapeutics at 362.0202 subject to Rule 16b-3 | 11/18/2024 |
16 | United Therapeutics president sells shares worth 3.59 million | 11/19/2024 |
17 | United Therapeutics EVP sells shares worth 2.8 million | 11/22/2024 |
Additional Tools for United Stock Analysis
When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.